The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion
Published: 13 September 2021
In this series, on behalf of the investigators, Dr Mikhail Kosiborod (St Luke’s Mid America Heart Institute, Kansas City, US) and Dr Dalane Kitzman (Wake Forest School of Medicine, North Carolina, US) address the PRESERVED-HF study.
In the first part of the programme, Dr Mikhail Kosiborod provides a comprehensive overview of the study, summarising the challenge of heart failure with Preserved Ejection Fraction, the study design, and key endpoints. Dr Kosiborod highlights that dapagliflozin significantly improved symptoms and physical limitations in patients with HFpEF at 12 weeks. The treatment effect was meaningful and statistically significant, with no safety signals.
In the second part of the programme, Dr Kosiborod is joined by Dr Kitzman for a peer-to-peer discussion. Each short video of this engaging four-part series takes a detailed look at the study: together, they access the study design, recap the main results, consider important baseline characteristics, and tackle the implications of this data for real world practice.
- Recall the symptom and physical limitation improvements achieved in PRESERVED-HF
- Describe the characteristics of the PRESERVED-HF study patient population in the context of real-world patients
- Discuss the potential clinical implications of PRESERVED-HF to the treatment of patients with HFpEF
PRESERVED-HF: Main Study Presentation
Dr Kosiborod is an internationally recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, and quality care and outcomes.
He is a cardiologist, Vice President of Research at Saint Luke's Health System, Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.